Stem Cell Clinic

Stem Cell Therapy Market Comprehensive Analysis, Growth Forecast From 2020 To 2026 – Cole of Duty

Global Stem Cell Therapy Market Size, Status And Forecast 2020-2026

Global Stem Cell Therapy Market Size research report with COVID-19 impact is considered to be an extremely intelligent and deep assessment of the present industrial conditions along with the overall Stem Cell Therapy market size estimated from 2020 to 2026. The study report also showcases a comprehensive analysis of the leading business programs, Stem Cell Therapy future market share, and business-oriented planning, etc. The report investigates desirable factors related to the current industrial situations, Stem Cell Therapy market growth rates, demands, differentiable business-oriented strategies used by the Stem Cell Therapy market manufacturers/Key players concerning distinct tactics and the futuristic prospects in brief.

(Special Offer: Available up to 30% Discount for a limited time only):

Get a Free Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/05052012760/global-stem-cell-therapy-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread/inquiry?source=colodduty&Mode=54

The research report is a compilation of key data with regards to the competitive landscape of this vertical and the multiple regions where the business has successfully established its position.

Top Companies in the Global Stem Cell Therapy Market: MEDIPOST,Holostem Terapie Avanzate,Anterogen,NuVasive,Osiris Therapeutics,BIOTIME,RTI Surgical,AlloSource,JCR Pharmaceuticals,BrainStorm Cell Therapeutics,Pharmicell,Advanced Cell Technology,Caladrius.and others.

This report segments the global Stem Cell Therapy market on the basis of Types are:

On the basis of Application, the Global Stem Cell Therapy market is segmented into:

For comprehensive understanding of market dynamics, the global Stem Cell Therapy market is analyzed across key geographies namely: United States, China, Europe, Japan, South-east Asia, India and others. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Avail Discount at

https://www.marketinsightsreports.com/reports/05052012760/global-stem-cell-therapy-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread/discount?source=colodduty&mode=54

-Comprehensive assessment of all opportunities and risk in the Stem Cell Therapy market.

-Stem Cell Therapy market recent innovations and major events.

-Detailed study of business strategies for growth of the Stem Cell Therapy market-leading players.

-Conclusive study about the growth plot of Stem Cell Therapy market for forthcoming years.

-In-depth understanding of Stem Cell Therapy market-particular drivers, constraints and major micro markets.

-Favourable impression inside vital technological and market latest trends striking the Stem Cell Therapy market.

Browse the report description and TOC:

https://www.marketinsightsreports.com/reports/05052012760/global-stem-cell-therapy-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread?source=colodduty&Mode=54

-Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

-Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

-Analytical Tools: The Global Stem Cell Therapy Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Customization of the Report: This report can be customized as per your needs for additional data up to 3 companies or countries or 40 analyst hours.

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc.MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

How we have factored the effect of Covid-19 in our report:

All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

IrfanTamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected] | [emailprotected]

More here:
Stem Cell Therapy Market Comprehensive Analysis, Growth Forecast From 2020 To 2026 - Cole of Duty

Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 – Cole of Duty

Global Stem Cell Therapy market report presents an overview of the market on the basis of key parameters such as market size, revenue, sales analysis and key drivers. The market size of global Stem Cell Therapy market is anticipated to grow at large scale over the forecast period (2020-2025). The main purpose of the study report is to give users an extensive viewpoint of the market. So that users can apply strategic processes to benchmark themselves against rest of the world. Key drivers as well as challenges of the market are discussed in the report. Also reports provides an in depth analysis of the Stem Cell Therapy market with current and future trends.

Get Sample Copy of this Report:https://www.adroitmarketresearch.com/contacts/request-sample/691

In addition, study report offers an array of opportunities for the players participating in the industry. This ultimately leads into the growth of the global Stem Cell Therapy market. Furthermore, report offers a comprehensive study on market size, revenue, sales, growth factors and risks involved in the growth of the market during the forecast period. The factors which are influencing the growth the market are mentioned in the report as well as the challenges which can hamper the growth of the market over the forecast period.

In addition, report presents quantitative as well as qualitative narration of global Stem Cell Therapy market. The research report is beneficial for educators, researchers, strategy managers, academic institutions and analysts. Thus report helps all types of users to identify the strategic initiatives so that they can understand how to expand the global Stem Cell Therapy market business across the globe for the product development. Moreover, research report provides in depth analysis of all the segments which can impact on the market growth.

Browse the complete report @https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

Global Stem Cell Therapy market is segmented based by type, application and region.

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Based on therapeutic application, the market has been segmented into,

Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

The company profile section also focusses on companies planning expansions along with mergers & acquisitions, new initiatives, R&D updates and financial updates. But, one of the most important aspects focused in this study is the regional analysis. Region segmentation of markets helps in detailed analysis of the market in terms of business opportunities, revenue generation potential and future predictions of the market. For Stem Cell Therapy report, the important regions highlighted are North America, South America, Asia, Europe and Middle East. The companies focused on in this report are pioneers in the Stem Cell Therapy market. Right from history to future plans the report give a detailed roadmap of the industry that the readers can rely on. The uplifting of any region in the global market is dependent upon the market players working in that region.

In the final section of the report on Stem Cell Therapy Market, the dashboard view of the companies is provided, to compare the current industrial scenario and their contribution in total Stem Cell Therapy Market. Moreover, it is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment. Report audiences can gain segment-specific manufacturer insights to identify and evaluate key competitors based on the in-depth assessment of their capabilities and success in the Stem Cell Therapy Marketplace.

For Any Query on the Stem Cell Therapy Market:https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX 75204, U.S.A Phone No.: USA: +1 972-362 -8199 / +91 9665341414

Read the original post:
Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 - Cole of Duty

Recovering from Cancer, a Stem Cell Transplant and Coronavirus – Cancer Health Treatment News

Dana-Farber Patient Recovering Well After Cancer and the Coronavirus

Pam Dobay is a warrior. In the last three years, the 67-year-old has dealt with a cancer diagnosis and stem cell transplant before recently contracting the coronavirus.

None of it was easy, but today, Dobay is recovering at home. She says she cannot begin to express the gratitude she feels towards everyone who has cared for her, including her Dana-Farber care team and her family.

When this is all over, I want to show everyone at Dana-Farber what they did, and thank them for everything, says Dobay.

A Blood Cancer Diagnosis

In February 2018, Dobay was diagnosed with myelofibrosis, a blood disorder in which the bone marrow is unable to produce healthy red blood cells. Dobays primary care physician first worried something wasnt right after her test results from routine blood work came back abnormal. Myelofibrosis is a precursor condition for leukemia, meaning it puts those who are diagnosed at a much higher chance of developing the disease.

Dobay, who lives in Holbrook, MA, was placed under the care ofCorey Cutler, MD, MPH, medical director of theAdult Stem Cell Transplantation Programat Dana-Farber/Brigham and Womens Cancer Center. Initially, she was given blood transfusions to help her body compensate for the bone marrows inability to produce red blood cells. This treatment is not designed to be a permanent fix, despite being highly effective for a short period of time: Eventually, Dobay would need a bone marrow transplant.

In September 2018, just six months after her diagnosis, Dobay underwent areduced-intensity transplant(sometimes referred to as a mini-transplant). Mini-transplant patients receive lower doses of chemotherapy than are used in a full-intensity transplant, and in general, receive no radiation therapy. The reduced-intensity procedure was developed for older patients and others who often cant tolerate the harsh side effects of full-intensity treatments.

The procedure still proved to be difficult for Dobay, who ended up in the intensive care unit (ICU) due to complications. This was a possibility her care team had prepared for, and slowly, her condition improved. While she still has some symptoms of chronic graft-versus-host disease (GVHD), she and her family including Robert Dobay, her husband of 45 years hoped this would be her toughest test.

This article was originally published on June 18, 2020, by Dana-Farber Cancer Institute. It is republished with permission.

The rest is here:
Recovering from Cancer, a Stem Cell Transplant and Coronavirus - Cancer Health Treatment News

Cancer Stem Cell Therapy Industry 2020: Global Market Trends, Size, Share, Growth Applications, SWOT Analysis by Top Key Players and Forecast Report…

TheGlobal Cancer Stem Cell Therapy Marketwas estimated to be valued at USD XX million in 2019 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026.

The market is primarily driven by increasing number of cancer patients suffering from many different types of cancer. In addition, stem cell therapy is a painless and incision less treatment procedure is likely to boost the market growth.

However, lack of suitable and donor matching sample might restrict the market growth.

Get Sample Copy of this Report @www.orianresearch.com/requestle/1040620

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

Top Key Companies Analyzed inGlobal Cancer Stem Cell Therapy Market are Thermo Fisher Scientific, Merck Kgaa, Bionomics, Lonza, Stemline Therapeutics, Miltenyi Biotec, Promocell, Macrogenics, Oncomed Pharmaceuticals and Irvine Scientific

Key Benefit of This Report:

Global Cancer Stem Cell Therapy Industry 2019 Market Research Report is spread across 121 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Inquire more or share a question if any before the purchase on this report @www.orianresearch.com/040620

Target Audience:

Research Methodology:

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective, such as, analyst reports of investment banks. The secondary research is the primary base of our study wherein we conducted extensive data mining, referring to verified data sources, such as, white papers, government and regulatory published articles, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end use trends and dynamics, and production capacity were taken into consideration.

Different weightages have been assigned to these parameters and quantified their market impacts using the weighted average analysis to derive the market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs), which typically include:

Get Direct Copy of this Report @www.orianresearch.com/checkout/1040620

Major Points Covered in Table of Contents:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Global Cancer Stem Cell Therapy Market Overview

5 Global Cancer Stem Cell Therapy Market, by Product Type

6 Global Cancer Stem Cell Therapy Market, by Application

7 Global Cancer Stem Cell Therapy Market by Region

8 Competitive Landscape

9 Company Profiles

10 Key Insights

Customization Service of the Report: Orian Research provides customisation of reports as per your need. This report can be personalised to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us: Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us: Ruwin Mendez Vice President Global Sales & Partner Relations Orian Research Consultants US: +1 (832) 380-8827 | UK: +44 0161-818-8027 Email:[emailprotected] Website: http://www.orianresearch.com/

Here is the original post:
Cancer Stem Cell Therapy Industry 2020: Global Market Trends, Size, Share, Growth Applications, SWOT Analysis by Top Key Players and Forecast Report...

Adipose Derived Stem Cell Therapy Market includes Production and Market Share by Type (2020-2026) – Cole of Duty

The globalAdipose Derived Stem Cell Therapy Marketreport by wide-ranging study of the Adipose Derived Stem Cell Therapy industry which covers comprehensively all aspects of the different industry verticals. This includes its past performance analysis, latest market performance estimation for the current year based on the drivers, challenges and trend. Furthermore, the future projection for the forecast period is also covered within the global Adipose Derived Stem Cell Therapy industry report. The Adipose Derived Stem Cell Therapy market segmentation provides the customer a comprehensive overview of the overall Adipose Derived Stem Cell Therapy industry, assisting them in making informed decisions through key insights into the Adipose Derived Stem Cell Therapy market. The segmentation is done on the basis of product, region, and application.

Major Players: Customized Adipose Derived Stem Cell Therapy Market: BioRestorative Therapies, Inc., Celltex Therapeutics Corporation, Antria, Inc., Cytori Therapeutics Inc., Intrexon Corporation, Mesoblast Ltd., iXCells Biotechnologies, Pluristem Therapeutics, Inc., Thermo Fisher Scientific, Inc., Tissue Genesis, Inc., Cyagen US Inc., Celprogen, Inc., and Lonza Group, among others.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2357

The PDF Research only provides Table of Contents (ToC), scope of the report and research framework of the report.

The report provides both quantitative and qualitative information of global Adipose Derived Stem Cell Therapy market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Adipose Derived Stem Cell Therapy is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Adipose Derived Stem Cell Therapy market was valued at USD _ million/billion.

We do offer a sample of this report. Kindly go through the following information in order to access sample copy.

This report sample includes

Brief Introduction to the research report. Table of Contents (Scope covered as a part of the study) Top players in the market Research framework (presentation) Research methodology adopted by Coherent Market Insights

Ask For Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2357

Market by Region:

North America (U.S., Canada, Mexico) Europe (Germany, U.K., France, Italy, Russia, Spain etc.) Asia-Pacific (China, India, Japan, Southeast Asia etc.) South America (Brazil, Argentina etc.) The Middle East and Africa (Saudi Arabia, South Africa etc.)

Key Content of Chapters as follows (Including and can be customized) :

Part 1: Market Overview, Development, and Segment by Type, Application & Region Part 2: Global Market by company, Type, Application & Geography Part 3-4: Asia-Pacific Market by company, Type, Application & Geography Part 5-6: Europe Market by company, Type, Application & Geography Part 7-8: North America Market by company, Type, Application & Geography Part 9-10: South America Market by company, Type, Application & Geography Part 11-12: Middle East & Africa Market by company, Type, Application & Geography Part 13: Company information, Sales, Cost, Margin etc. Part 14: Conclusion

Some Important Highlights From The Report Include:

Request Discount option enables you to get discounts on the actual price of the report. Kindly fill the form, and one of our consultants would get in touch with you to discuss your allocated budget and would provide discounts.

Use QUARANTINEDAYS Code In Precise Requirement And Get FLAT $1,000 OFF On This Reports

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/2357

Competitive Landscape

The analysts have provided a comprehensive analysis of the competitive landscape of the global Adipose Derived Stem Cell Therapy market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [emailprotected]

Read the original here:
Adipose Derived Stem Cell Therapy Market includes Production and Market Share by Type (2020-2026) - Cole of Duty

Ionis, leading MS researcher throw antisense at a new type of brain cells – Endpoints News

No matter how many molecules he threw at them, Paul Tesar couldnt get the brain cells to survive. Or he got them to survive, but then to everyones bafflement they still couldnt do what they were supposed to.

Tesar, a professor of innovative therapeutics at Case Western University, had spent years building stem cell models for multiple sclerosis, growing brain organoids in dishes and then seeing what small molecules restored myelin production. Now he was trying to do the same for other myelin diseases, particularly an ultra-rare genetic condition called Pelizaeus-Merzbacher disease, where a single mutation leads to the death of the myelin-producing neurons, called oligodendrocytes, and can kill patients in infancy.

Weve screened many thousands of small molecule compounds, Tesar toldEndpoints News. But we could not get them to restore function.

Then Tesar got an email from Ionis, the California biotech that had just used an RNA-modifying technology called antisense to build Spinraza, the first FDA-approved drug for the genetic neurological disorder spinal muscular atrophy.

Now, in a study published inNature,Tesar and Ionis have shown they can use a single dose of drug built from that technology to keep those neurons both alive and well-functioning and treat the disease at least in mice. The publication isnt groundbreaking, antisense researchers say, but it shows for the first time that antisense can be used to effectively target oligodendrocytes, an insight its authors hope will open up other rare myelin disorders to therapy.

Its not that its different than everything thats been done before, but it goes further than everything thats gone before, Jon Watts, a professor at the RNA Therapeutics Institute at UMass Medical School who is not affiliated with Ionis or the paper, told Endpoints, both in terms of duration of effect after a single dose, and the real focus in getting the biology, the therapeutic effect in oligodendrocytes.

The applicability to the most famous and common of myelin disorders, multiple sclerosis, is limited, researchers say, both because the therapy relied on having a specific gene to target and because the paper doesnt prove you can get an effect on the peripheral nervous system. Still, Berit Powers, an assistant director at Ioniss neurology research department and a co-author, pointed to several other genetic myelin disorders, known as leukodystrophies. That includes an Ionis program on Alexander disease, a rare childhood condition with Parkinsons-like symptoms.

Were certainly exploring the potential of ASOs in non-monogenic conditions like MS, Powers told Endpoints, using a shorthand for antisense oligonucleotides. But that work is very new.

This is hardly Tesars first foray into biotech. In 2015, he showed in Naturehow certain small molecules could regenerate myelin the holy grail for an MS therapy and founded Convelo Therapeutics around that work. Last year, they partnered with Genentech for an undisclosed sum and an exclusive option to acquire the company.

Myelin is a fatty substance that coats neurons, insulating them and helping electric currents pass through. Tesars lab was broadly interested in the question of why myelin fails, both in MS and rare diseases, and about 7 years ago he got a grant to work from the PMD Foundation.

First, Tesar built stem cell models of the disease, figuring out how different mutations in a single gene, called PLP1, lead oligodendrocyte progenitor cells (the stem cell-like cells that will become oligodendrocytes) to create a toxic RNA and a mutated protein that kills them soon after they differentiate. Then, he tried to suppress that gene with different chemicals, eventually testing over 3,000 different compounds.

He was able to eventually get the oligodendrocytes to survive, but to his surprise, they didnt produce myelin as they should. The surviving cells still couldnt properly function, revealing, he wrote in a 2018 Cell paper a second phase of pathology. A hypothetical treatment, he argued, would have to both keep progenitor cells alive and then treat the survivors in a way that induces myelination.

With antisense, he and Powers Ionis team were able to do both. Antisense oligonucelotides consist of strands of RNA that are a mirror image of the RNA you want to target. The mirror binds to and silences, or turns off, that gene. In the study, the researchers confirmed that PLP1 was disease-causing by knocking out the gene in cell lines with CRISPR. Then they injected mice with antisense strands through the spinal cord, the same way Spinraza is delivered. (You cant use CRISPR to treat the disease in humans, because theres no good way yet of delivering it.)

Powers and Tesar were unsure if they would be able to target oligodendrocytes and progenitor cells. What they found, though, was complete restoration of oligodendrocytes and a profound rescue of neurological function. Myelin, too, was finally restored. Mice that died after 3 weeks now lived for over 200 days.

Ionis hasnt licensed the drug and its unclear yet the implications for other diseases, but researchers say the results could translate into humans quickly, at least by drug development standards.

I do think its very rapidly translatable, Watts said. Based on the data theyre showing here, and based on the unmet need, this appears to be something that could be translated pretty quickly into a Phase I trial.

Read more from the original source:
Ionis, leading MS researcher throw antisense at a new type of brain cells - Endpoints News

Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder – Newswise

Newswise Massachusetts Eye and Ear, a member hospital of Mass General Brigham, is entering into an exclusive licensing agreement with Biogen to develop a potential treatment for inherited retinal degeneration due to mutations in the PRPF31 gene, which are among the most common causes for autosomal dominant retinitis pigmentosa.

Inherited retinal degenerations (IRDs), such as retinitis pigmentosa, are a group of blinding eye diseases caused by mutations in over 270 different genes. Mutations in the PRPF31 gene are the second most common cause of dominant IRD and lead to defects in the function of the retinal pigment epithelial (RPE) cells and photoreceptors of the retina. Previous lab-based research performed by members of the Ocular Genomics Institute at Harvard Ophthalmology, led by Eric A. Pierce, MD, PhD, demonstrated that adeno-associated virus (AAV)-mediated gene augmentation therapy for PRPF31 can restore normal function to PRPF31 mutant RPE cells.

Biogen (Nasdaq: BIIB), a biopharmaceutical company that discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies, will build upon this prior work, and conduct the studies needed for clinical development of PRPF31 gene therapy. This includes the pre-clinical studies needed to support progression to clinical trials of PRPF31 gene therapy. As part of the agreement, Biogen will receive an exclusive license to develop the product worldwide and will be responsible for all U.S. Food and Drug-Administration (FDA) required investigational new drug (IND) enabling studies, clinical development and commercialization.

The treatment of IRDs with highly effective AAV-based gene therapies is core to Biogens ophthalmology strategy, said Chris Henderson, Head of Research, Biogen. This agreement underscores our commitment to that strategy and builds off of our acquisition of Nightstar Therapeutics in 2019 and our active clinical trials of gene therapies for different genetic forms of IRD. We are excited to work with Massachusetts Eye and Ear and look forward to applying our preclinical and clinical experience to their leading PRPF31 program.

We are thrilled to work with Biogen, who will bring to this effort its deep experience with the clinical development process, as we work toward our goal of developing a gene therapy for people with PRPF31-related eye disease, added Dr. Pierce, who is the William F. Chatlos Professor of Ophthalmology at Harvard Medical School. My ultimate hope for patients with inherited retinal disorders due to mutations in PRPF31 is that a gene therapy will preserve and potentially restore some of their vision.

About the Ocular Genomics Institute

The Ocular Genomics Institute at Harvard Ophthalmology aims to translate genomic medicine into precision ophthalmic care for patients with inherited eye disorders. It is home to one of the leading centers for early-phase clinical trials of therapies for inherited retinal degenerations, with seven gene-based and one stem cell trial currently in progress. The group works in conjunction with other departments throughout Harvard Medical School and Mass. Eye and Ear, including the Bioinformatics Center and Grousbeck Gene Therapy Center.

Dr. Pierces lab, established in 2011, is dedicated to research in an effort to improve the understanding of the molecular bases of IRDs so that rational therapies can be developed for these diseases.

In 2018, Mass. Eye and Ear surgeons performed the first post-FDA approval gene therapy for patients with a form of inherited retinal blindness caused by mutations in the gene RPE65 by injecting an AAV-based drug treatment into a patients eye, which restored vision in a 13-year-old boy. This therapy, called Luxturna, is now being used to treat patients with RPE65-associated retinal degeneration around the world.

One of the exciting aspects of our collaboration with Biogen is that mutations in the PRPF31 gene affect approximately 10 to 20 times more people than mutations in the RPE65 gene, said Dr. Pierce. Success with PRPF31 gene therapy could provide visual benefit to more patients, which is our ultimate goal.

Mass. Eye and Ear was one of the first centers to offer life-changing gene therapies to patients with inherited retinal disease, and we are thrilled with this new opportunity to develop a translational retinal therapy that could help even more patients, said Joan W. Miller, MD, Chief of Ophthalmology at Mass. Eye and Ear, Massachusetts General Hospital, and Brigham and Womens Hospital, and Chair of Ophthalmology and the David Glendenning Cogan Professor of Ophthalmology at Harvard Medical School.

According to Chris Coburn, Chief Innovation Officer, Mass General Brigham, the collaboration with Biogen illustrates the importance of academia and industry teaming to solve problems for patients worldwide. We are eager to see this progress reach patients who are challenged by blinding, degenerative eye disease, said Coburn. We look forward to working with Biogen to advance this break-through innovation.

Patients with an inherited retinal disease require genetic testing prior to being considered for any gene therapy treatment.

About Massachusetts Eye and Ear

Massachusetts Eye and Ear, founded in 1824, is an international center for treatment and research and a teaching hospital of Harvard Medical School. A member of Mass General Brigham, Mass. Eye and Ear specializes in ophthalmology (eye care) and otolaryngologyhead and neck surgery (ear, nose and throat care). Mass. Eye and Ear clinicians provide care ranging from the routine to the very complex. Also home to the world's largest community of hearing and vision researchers, Mass. Eye and Ear scientists are driven by a mission to discover the basic biology underlying conditions affecting the eyes, ears, nose, throat, head and neck and to develop new treatments and cures. In the 20192020 Best Hospitals Survey,U.S. News & World Reportranked Mass. Eye and Ear #4 in the nation for eye care and #2 for ear, nose and throat care.For more information about life-changing care and research at Mass. Eye and Ear, visit our blog,Focus, and follow us onInstagram,TwitterandFacebook.

About Harvard Medical School Department of Ophthalmology

The Harvard Medical SchoolDepartment of Ophthalmologyis one of the leading and largest academic departments of ophthalmology in the nation. Composed of nine affiliates (Massachusetts Eye and Ear, which is home to Schepens Eye Research Institute; Massachusetts General Hospital; Brigham and Womens Hospital; Boston Childrens Hospital; Beth Israel Deaconess Medical Center; Joslin Diabetes Center/Beetham Eye Institute; Veterans Affairs Boston Healthcare System; Veterans Affairs Maine Healthcare System; and Cambridge Health Alliance) and several international partners, the department draws upon the resources of a global team to pursue a singular goaleradicate blinding diseases so that all children born today will see throughout their lifetimes. Formally established in 1871, the department is committed to its three-fold mission of providing premier clinical care, conducting transformational research, and providing world-class training for tomorrows leaders in ophthalmology.

Continue reading here:
Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder - Newswise

Canine Arthritis Treatment Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape, Forecast-…

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Elanco (Eli Lilly and Company), Boehringer Ingelheim, Zoetis Inc., Vetoquinol S.A., Bayer AG, Aratana Therapeutics Inc., Norbrook Laboratories Limited, VetStem Biopharma, and Dechra Pharmaceuticals Plc, among others. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The Canine Arthritis Treatment Market is expected to exceed more than US$ 3.18 Billion by 2024 at a CAGR of 4.4% in the given forecast period.

Browse Full Report: https://www.marketresearchengine.com/canine-arthritis-treatment-market

FYI, You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports will now feature detailed analysis that will help you make critical decisions.

The Canine Arthritis Treatment Market is segmented on the lines of its treatment type, route of administration, end users and regional. Basis of End-User is segmented into Veterinary Hospitals and Clinics, Retail Pharmacies, Drug Stores and E-commerce. Based on Treatment Type it covers Non-steroidal anti-inflammatory drugs, Opioids and Stem Cell Therapy. Based on route of administration it covers Oral and Injectable. The Canine Arthritis Treatment Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

Reasons to Buy this Report:

1) Obtain the most up to date information available on all Canine Arthritis Treatment Market.

2) Identify growth segments and opportunities in the industry.

3) Facilitate decision making on the basis of strong historic and forecast of Canine Arthritis Treatment Market.

4) Assess your competitors refining portfolio and its evolution.

Canine arthritis may be a chronic condition that ends up in inflammation of 1 or a lot of joints and progresses over time if left untreated. the foremost usually affected joints embody the knee, elbow, shoulder, hip and back. There are numerous causes of inflammatory disease in dogs like traumatic injuries, obesity, failure of correct bone development and lots of others. There are many sorts of canine arthritis however the foremost common is arthritis. It affects one in five adult dogs. The prevalence of arthritis will increase with the age of canines. Its a chronic disease characterised by the loss of gristle. It conjointly includes alternative abnormalities like osteophytotic in response to inflammation and pain.

The Canine Arthritis Treatment Market has been segmented as below:

By Treatment Type:

By Route of Administration:

By End-User:

This report provides:

1) An overview of the global market for Canine Arthritis Treatment Market and related technologies. 2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2024. 3) Identifications of new market opportunities and targeted promotional plans for Canine Arthritis Treatment Market.

4) Discussion of research and development, and the demand for new products and new applications. 5) Comprehensive company profiles of major players in the industry.

Report Scope:

The scope of the report includes a detailed study of Canine Arthritis Treatment Market with the reasons given for variations in the growth of the industry in certain regions.

Request Sample Report from here: https://www.marketresearchengine.com/canine-arthritis-treatment-market

Table of Contents

4.1 Introduction

4.2 Drivers

4.3 Restrains

4.4 Industry Trends

4.5 Porters Five Forces Analysis

10.1 Elanco (Eli Lilly and Company)

10.2 Norbrook Laboratories Limited

10.3 Aratana Therapeutics Inc.

10.4 Dechra Pharmaceuticals Plc

10.5 VetStem Biopharma

10.6 Zoetis Inc.

10.7 Vetoquinol S.A.

10.8 Boehringer Ingelheim

10.9 Bayer AG

Other Related Market Research Reports:

Cardiac Assist Devices Market is Supposed to Reach at a CAGR of 10.02% by 2024

Cardiac Rehabilitation Devices Market is Supposed to Reach US$ 170 Billion by 2024

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Go here to read the rest:
Canine Arthritis Treatment Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape, Forecast-...

Global Microcarrier System Market to Record Significant Rise in Revenue Share Owing to the Augmenting Demand in COVID 19 Pandemic – 3rd Watch News

Microcarrier system offers a system matrix which would develops the growth of adherent cells in bioreactors. Microcarrier system is beneficial for a numerous of parameters such as better cell yields, large culture surface area, and also decrease the risk of contamination which will provide advantage to the growth of global microcarrier system market. A shrill trend in the application of microcarrier system is for treatment of wide conditions and cost-effective therapy which are propelling the growth of the microcarrier system market. Additionally microcarrier system market working on marketing strategies so that potential population can access to biopharmaceuticals.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/31443

The major driving factor for microcarrier system market is growing inclination towards research & development activities in cell therapy research as well as the favorable funding is anticipated to drive growth within the stem cell therapy sector. The emerging demand for microcarrier system market is largely arising from the increasing incidences of cancer. Growing demand for stem cell therapy coupled with growing adoption for cell-based vaccines will foster the microcarrier system market growth. The endlessly increasing cost-effective cell production for numerous stem cell therapies in large scale is fueling the demand for microcarrier system market. Moreover, the growing demand for detection of numerous other diseases for instance cancer and other hereditary diseases increases the probabilities for stem therapy techniques consequently increasing demand for microcarrier system market. As well as manufacturers are focusing on developing innovative techniques for stem cell therapy which will boost the growth of the microcarrier system market. However, limitations in the production of high-density cell culture can restrain the growth of microcarrier system market.

The global microcarrier system market is segmented on the basis of Product Type, Application, End User and Geography:

The global microcarrier system market is into initial stages attributed to focus on acclimatizing to the new technique in stem cell therapy and its innovation. Consequently, the microcarrier system is projected to demonstrate exponential growth potential for the treatment of cancer patient owing to a higher inclination towards cost-effective therapy cost. The major parameter in the microcarrier system market is concentrating on increased manufacturing efficacy with effective therapies to the patient. The increasing new applications in hereditary diseases are anticipated to offer growth opportunities for the microcarrier system market. However recent development in the growth of adherent cells can boost microcarrier system market, for instance in 2018, the newly designed system for the development of adherent cells on microcarriers and rapid process development of vaccines was launched by Sartorius Stedim Biotech (SSB) which is mini bioreactor vessel for ambr 250.

You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/31443

Geographically, the global microcarrier system market is segmented into regions such as Latin America, Europe, North America, South Asia, East Asia Middle East & Africa and Oceania. North America is projected to emerge as a prominent market in the global microcarrier system market due to favorable reimbursement scenarios and superior healthcare infrastructure. Increase in research funds which are provided by various biopharmaceutical companies will fuel the growth of global microcarrier system market in European countries like France, the UK, Spain, Germany, and others. The microcarrier system market in south Asia and East Asia is expected to grow substantially due to the high number of patient population and growing demand for cell-based vaccines. The Middle East and Africa (MEA) can make symbolic progress due to increasing investment in the Middle Eastern countries like Israel, Dubai, and others.

Some of the major key players competing in the global microcarrier system Market are General Electric Company, Thermo Fisher Scientific Inc., Lonza Group, Eppendorf, HiMedia Laboratories, Merck KGaA, Danaher Corporation, Becton, Dickinson and Company and Corning Incorporated, The Sartorius group and among others.

Continue reading here:
Global Microcarrier System Market to Record Significant Rise in Revenue Share Owing to the Augmenting Demand in COVID 19 Pandemic - 3rd Watch News

Context Therapeutics Announces Publication of Onapristone Extended Release Safety Review Results – Business Wire

PHILADELPHIA--(BUSINESS WIRE)--Context Therapeutics LLC, a clinical-stage biopharmaceutical company dedicated to advancing medicines for hormone driven cancers, today announced that results from a safety review from preclinical and two Phase 1-2 studies evaluating its drug candidate onapristone extended release (ONA-ER) for the treatment of progesterone receptor (PR) positive cancers has been published in the journal Drug Safety. ONA-ER is an investigational, potentially best-in-class oral progesterone receptor (PR) antagonist. If approved, ONA-ER would be the first FDA-approved medication for PR+ cancers.

Antiprogestins demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the advancement of this therapeutic class. Onapristone was previously evaluated in Phase 2 studies for metastatic breast cancer. Due to liver enzyme elevations identified during these studies, further development was halted. Evaluation of antiprogestin pharmacology and pharmacokinetic (PK) data suggests that liver enzyme elevations might be related to off-target effects associated with serum Cmax levels. If correct, this suggests the use of pharmaceutic strategies targeting efficacious systemic dose levels, but with a diminished Cmax. One such strategy twice-daily dosing of an extended release (ER) formulation of onapristone (ONA-ER) was developed and clinically evaluated in two phase 1-2 studies in PR-positive malignancies. In light of renewed interest in antiprogestin therapy for treating PR-positive breast and gynecologic cancer, the publication authors assessed the hepatotoxic potential of: (a) onapristone in liver-focused preclinical toxicology models, and (b) ONA-ER based on data from two phase 1-2 studies involving breast, ovarian, endometrial, and prostate cancer patients.

These results suggest that the extended-release formulation by reducing drug exposure may be associated with a reduced risk of hepatotoxicity, and supports the continued clinical evaluation of ONA-ER for treating PR-positive cancers, said study author James H. Lewis, MD, Director of Hepatology at MedStar Georgetown University Hospital.

In the Phase 1-2 trials, ONA-ER at escalating doses of 10 mg to 50 mg twice-a-day had a favorable safety and tolerability profile at all doses. There were no treatment-related severe adverse events among patients treated with ONA-ER. No clinical trial subject receiving ONA-ER developed liver test elevations meeting Hys Law criteria or other clinically significant hepatic injury considered to be drug-related.

Poor tolerability has limited the potential of antiprogestins for cancer patients, said Martin Lehr, Chief Executive Officer of Context. We are pleased with the results from this review, which highlight the potential of ONA-ER to meet a significant unmet need for a well tolerated treatment for PR-positive cancers.

About Onapristone ER

Onapristone ER (extended release) is a potent and specific antagonist of the progesterone receptor that is orally administered. Currently, there are no approved therapies that selectively target progesterone receptor (PR) positive cancers. Preclinical and clinical data suggest that onapristone ER has anticancer activity by inhibiting progesterone receptor binding to chromatin, downregulating cancer stem cell mobilization and blocking immune evasion. Onapristone ER is currently being evaluated in patients with PR+ rare ovarian and endometrial cancers in the ongoing Phase 2 ONWARD 220 clinical trial. Additional Phase 2 clinical trials in ER+, PR+, HER2- breast cancer and PR-positive endometrial cancers will be initiated in 2020. Onapristone ER is an investigational drug that has not been approved for marketing by any regulatory authority.

About Context Therapeutics

Context Therapeutics LLC is a clinical-stage biopharmaceutical company advancing medicines to treat hormone driven cancers. Contexts lead program is onapristone ER, an investigational Phase 2 drug that is being developed for progesterone receptor positive breast, ovarian and endometrial cancers. For more information on Context, visit http://www.contexttherapeutics.com.

Here is the original post:
Context Therapeutics Announces Publication of Onapristone Extended Release Safety Review Results - Business Wire